Clinical trials: Haemodialysis
Hyperphosphatemia
Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia.
- Trial name
- NCT04771780
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 213 people
- Sponsor
- Kyowa Kirin Co., Ltd.
End Stage Renal Disease
Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
The InterGraft™ Venous Anastomotic Connector provides an endovascular, minimally invasive means for attachment of an arteriovenous graft to a vein in the upper extremity.
- Trial name
- NCT02532621
- Testing
- Venous InterGraft Connector, sutured arterial anastomosis of an implanted vascular graft for hemodialysis, hemodialysis
- Where
- 10 sites in United States
- Volunteers
- 158 people
- Sponsor
- Phraxis, Inc.
Anemia, Kidney Failure
Dynepo Infrequent Dosing Study
The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as measured by haemoglobin at week 24 and…
- Trial name
- NCT00450333
- Testing
- Dynepo (Epoetin delta), Dynepo
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 407 people
- Sponsor
- Shire
Anemia, Chronic Kidney Disease
Peginesatide for Anemia in Chronic Hemodialysis Patients
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00228449
- Testing
- peginesatide
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Affymax
Renal Dialysis, Kidney Failure, Chronic
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with…
- Trial name
- NCT03873038
- Testing
- MK-2060
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Uremic Pruritus
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
- Trial name
- NCT03281538
- Testing
- CR845
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- Cara Therapeutics, Inc.
Hyperphosphatemia
Dose-finding Study of KHK7791 in Hyperphosphatemia Patients
To evaluate the effect and safety of KHK7791 to treat Hyperphosphatemia in ptatients on HD.
- Trial name
- NCT03864458
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 207 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Multiple Myeloma
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
The primary purpose of the study is to determine the safety and efficacy and to generate PK and biomarker data for the combination of Pomalidomide and low-dose Dexamethasone in patients with relapsed or refractory multiple…
- Trial name
- NCT02045017
- Testing
- Pomalidomide and Dexamethasone
- Where
- 22 sites in Austria, France and 6 more
- Volunteers
- 81 people
- Sponsor
- Celgene
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
The primary objective was to characterize corrected serum calcium levels on treatment with cinacalcet in pediatric patients with secondary hyperparathyroidism (HPT).
- Trial name
- NCT01439867
- Testing
- Cinacalcet hydrochloride, Standard of Care
- Where
- 42 sites in United States, Belgium and 11 more
- Volunteers
- 18 people
- Sponsor
- Amgen
Uremic Pruritus in Hemodialysis Patients
A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus
The purpose of this study is to evaluate the efficacy, safety and dose response of SK-1405 for the treatment of subjects with uremic pruritus receiving hemodialysis, during 2 weeks of treatment.
- Trial name
- NCT03218501
- Testing
- SK-1405 high dose, SK-1405 low dose
- Where
- Japan
- Volunteers
- 269 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
End Stage Renal Failure on Dialysis, Hyperplasia
Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access
The purpose of this study is to determine whether the long term use of the experimental Vascular Wrap(TM) Paclitaxel-Eluting Mesh is safe in the treatment of subjects needing hemodialysis access (via an expanded…
- Trial name
- NCT01033357
- Testing
- Graft, Vascular Wrap, Lifespan® ePTFE Vascular Graft Only
- Where
- 30 sites in United States
- Volunteers
- 222 people
- Sponsor
- Angiotech Pharmaceuticals
End Stage Renal Disease
Evaluation of STARgraft AV for Hemodialysis Access
This study is a First-in-Human, single site, prospective, randomized, controlled evaluation of the safety and effectiveness of the Healionics STARgraft AV hemodialysis access graft.
- Trial name
- NCT03916731
- Testing
- STARgraft AV, ePTFE AV graft (control)
- Where
- Paraguay
- Volunteers
- 55 people
- Sponsor
- Healionics Corporation
Kidney Failure, Chronic
Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects
The primary objective of the study was to compare the single dose pharmacokinetics of alisporivir in subjects with end stage renal disease (ESRD) on hemodialysis to those of matched healthy subjects.
- Trial name
- NCT01975337
- Testing
- Alisporivir
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Debiopharm International SA
Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
The objective of this study is to examine the clinical dose range of ASP1585 based on the efficacy, safety, and feasibility of treatment in chronic kidney disease patients on hemodialysis with hyperphosphatemia.
- Trial name
- NCT02753894
- Testing
- ASP1585
- Where
- 11 sites in Japan
- Volunteers
- 73 people
- Sponsor
- Astellas Pharma Inc
Stenosis of Native Hemodialysis Arteriovenous Fistulas
ACOART AVF RENEW: A Post Market Clinical Study
The objective of this prospective，multi-center，single arm study is to obtain further data on the safety and performance of the Acotec Orchid＆Dhalia Drug-coated Balloon catheters for the treatment of for the obstructive lesions in…
- Trial name
- NCT06205576
- Testing
- DCB catheter
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Acotec Scientific Co., Ltd
CKD Anemia in Stable Dialysis Patients
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.
- Trial name
- NCT02273726
- Testing
- Epoetin Alfa, Roxadustat
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 741 people
- Sponsor
- Kyntra Bio
Renal Dialysis
Study of Self-monitoring of Weight & Blood Pressure (Via patientMpower Platform) in Hemodialysis
Pilot-scale study to assess the effect of self-monitoring using the patientMpower electronic health journal (pMp app) [+digital weighing scales \& BP monitor] on outcomes in ambulatory haemodialysis patients.
- Trial name
- NCT03403491
- Testing
- patientMpower application
- Where
- Ireland
- Volunteers
- 43 people
- Sponsor
- patientMpower Ltd.
Chronic Kidney Disease, Renal Dialysis
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.
- Conditions
- Chronic Kidney Disease, Renal Dialysis, Renal Insufficiency, Hyperphosphatemia
- Trial name
- NCT00892749
- Testing
- ASP1585
- Where
- 4 sites in Japan
- Volunteers
- 248 people
- Sponsor
- Astellas Pharma Inc
Kidney Failure
Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
The purpose of this study is to determine the quantity of iron derived from SFP that is transferred from the dialysate to patients during a single dialysis session.
- Trial name
- NCT01894906
- Testing
- Soluble Ferric Pyrophosphate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockwell Medical Technologies, Inc.
End Stage Renal Disease
Comparison of Daily Home Hemodialysis (HD) With Conventional in Center HD in Terms of Patients Quality of Life and Clinical Outcomes
The objective of this study is to describe the characteristics of patients on daily home hemodialysis and to confirm in real practice in France the effectiveness shown in studies, mainly American, both in terms of clinical…
- Trial name
- SeCoIA (NCT03737578)
- Testing
- Delivery of a connected pedometer / accelerometer
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Physidia